Source comparison
Comparison: Melanotan-1 EPP Treatment Results Timeline vs Other Melanotropic Peptides
Melanotan-1 (Afamelanotide) MC1R selective agonist 3–7 days 8–12 weeks Week 3 (measurable reduction in EPP phototoxicity) Minimal. Nausea <5%, flushing rare FDA-approved for EPP; most predictable timeline and safety profile for photoprotection Melanotan-II MC1
This comparison does not assign a generated winner or score.
- Melanotan-1 (Afamelanotide)
- MC1R selective agonist
- 3–7 days
- 8–12 weeks
- Week 3 (measurable reduction in EPP phototoxicity)
- Minimal. Nausea <5%, flushing rare
- FDA-approved for EPP; most predictable timeline and safety profile for photoprotection
- Melanotan-II
- MC1R + MC3R + MC4R agonist
- 2–5 days
- 4–8 weeks
- Week 2 (faster due to higher receptor promiscuity)
- High. Nausea 30–50%, spontaneous erections, hypertension
- Faster pigmentation but unacceptable side effect profile; not approved for human use
- Natural α-MSH
- Endogenous MC1R ligand
- Variable (UV-dependent)
- 14–21 days (UV-dependent)
- Only with continued UV exposure
- None (endogenous)
- Requires UV damage signal; not viable for EPP photoprotection